amantadine has been researched along with Disease Exacerbation in 25 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amantadine may augment virological response rates to interferon-based therapy in chronic hepatitis C patients." | 9.12 | Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. ( Brunner, H; Datz, C; Ferenci, P; Formann, E; Gangl, A; Gschwantler, M; Hackl, F; Hubmann, R; Kessler, HH; Klingler, A; Laferl, H; Stauber, R; Steindl-Munda, P, 2006) |
| "Amantadine is sometimes used to treat fatigue in multiple sclerosis." | 8.02 | Delayed amantadine toxicity causing apparent progression of multiple sclerosis. ( Bradley, L, 2021) |
| "Amantadine treatment was not associated with CD81 expression." | 5.36 | Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C. ( Hartmann, RW; Herrmann, E; Hofmann, WP; Kronenberger, B; Ochs, D; Piiper, A; von Wagner, M; Welker, MW; Zeuzem, S; Zimmer, V, 2010) |
| "Amantadine may augment virological response rates to interferon-based therapy in chronic hepatitis C patients." | 5.12 | Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. ( Brunner, H; Datz, C; Ferenci, P; Formann, E; Gangl, A; Gschwantler, M; Hackl, F; Hubmann, R; Kessler, HH; Klingler, A; Laferl, H; Stauber, R; Steindl-Munda, P, 2006) |
| "Amantadine is sometimes used to treat fatigue in multiple sclerosis." | 4.02 | Delayed amantadine toxicity causing apparent progression of multiple sclerosis. ( Bradley, L, 2021) |
| "amantadine was withdrawn in all patients." | 2.70 | Amantadine for dyskinesia in patients affected by severe Parkinson's disease. ( Onofrj, M; Paci, C; Thomas, A, 2001) |
| "Parkinson disease is a complex neurodegenerative disease with both motor and nonmotor symptoms." | 2.44 | Parkinson disease: managing a complex, progressive disease at all stages. ( Giroux, ML, 2007) |
| "ET tremor is usually characterized by symmetric bilateral postural and kinetic tremor, which may respond to low alcohol consumption." | 2.44 | [Diagnosis and treatment of tremor in Parkinson's disease and essential tremor]. ( Benecke, R; Wolters, A, 2007) |
| "Optimal management of Parkinson's disease patients requires careful titration of medications, with use of polypharmacy, including levodopa, dopamine agonists, catechol-O-methyltransferase inhibitors, amantadine, and anticholinergics in order to maintain good motor function and quality of life." | 2.41 | Parkinson's disease: medical treatment of moderate to advanced disease. ( Suchowersky, O, 2002) |
| "Fatigue is a common symptom in patients with multiple sclerosis." | 2.40 | ['Fatigue' in multiple sclerosis]. ( Hohlfeld, R; Zimmermann, C, 1999) |
| "Levodopa is the most effective medical treatment for Parkinson disease." | 1.38 | Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease. ( Tarsy, D, 2012) |
| "In patients who had impulse control disorders at baseline (n = 119), high dopamine agonist dose was associated with the presence of disorders at follow-up." | 1.38 | Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. ( Joutsa, J; Kaasinen, V; Martikainen, K; Vahlberg, T, 2012) |
| "The manifestations of daytime somnolence and abnormal sleep behavior have been described in SCA type 3 (SCA3) and SCA type 6 (SCA6), but as yet have not been described in SCA type 1 (SCA1)." | 1.36 | Excessive daytime somnolence in spinocerebellar ataxia type 1. ( Cunnington, D; Dang, D, 2010) |
| "Amantadine treatment was not associated with CD81 expression." | 1.36 | Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C. ( Hartmann, RW; Herrmann, E; Hofmann, WP; Kronenberger, B; Ochs, D; Piiper, A; von Wagner, M; Welker, MW; Zeuzem, S; Zimmer, V, 2010) |
| "Motor complications and disease progression are responsible for devastating morbidity." | 1.32 | A young onset Parkinson's patient: a case study. ( Jung, SK, 2004) |
| "It is mainly related to disease progression and levodopa treatment." | 1.31 | Freezing of gait in patients with advanced Parkinson's disease. ( Giladi, N; Kandinov, B; Korczyn, AD; Orlov, Y; Paleacu, D; Shabtai, H; Simon, ES; Treves, TA, 2001) |
| "Amantadine-treated patients (n = 250) were similar to the patients not treated with amantadine (n = 586) in terms of age, gender, type of parkinsonism, Hoehn and Yahr stage and dementia status at initial neurological visit." | 1.29 | Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. ( Ahlskog, JE; Basran, P; Ho, MM; Offord, KP; Prasad, M; Rajput, A; Rajput, AH; Schroeder, DR; Uitti, RJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 13 (52.00) | 29.6817 |
| 2010's | 9 (36.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradley, L | 1 |
| Kestenbaum, M | 1 |
| Abu Snineh, M | 1 |
| Nussbaum, T | 1 |
| Gadoth, A | 1 |
| Rosenberg, A | 1 |
| Hindi, A | 1 |
| Zitser, J | 1 |
| Thaler, A | 1 |
| Giladi, N | 3 |
| Gurevich, T | 1 |
| Yang, TW | 1 |
| Park, B | 1 |
| Kim, KT | 1 |
| Jun, JS | 1 |
| Kim, YS | 1 |
| Lee, ST | 1 |
| Jung, KH | 1 |
| Chu, K | 1 |
| Lee, SK | 1 |
| Jung, KY | 1 |
| Vonder Haar, C | 1 |
| Lam, FC | 1 |
| Adams, WK | 1 |
| Riparip, LK | 1 |
| Kaur, S | 1 |
| Muthukrishna, M | 1 |
| Rosi, S | 1 |
| Winstanley, CA | 1 |
| Nair, S | 1 |
| Lipscomb, J | 1 |
| Eason, J | 1 |
| Husain, M | 1 |
| Shukla, R | 1 |
| Dikshit, M | 1 |
| Maheshwari, PK | 1 |
| Nag, D | 1 |
| Srimal, RC | 1 |
| Seth, PK | 1 |
| Khanna, VK | 1 |
| Dang, D | 1 |
| Cunnington, D | 1 |
| Welker, MW | 1 |
| von Wagner, M | 1 |
| Ochs, D | 1 |
| Zimmer, V | 1 |
| Hofmann, WP | 1 |
| Piiper, A | 1 |
| Hartmann, RW | 1 |
| Herrmann, E | 1 |
| Zeuzem, S | 1 |
| Kronenberger, B | 1 |
| Fernandez, HH | 1 |
| Tarsy, D | 1 |
| Regragui, W | 1 |
| Lachhab, L | 1 |
| Razine, R | 1 |
| Benjelloun, H | 1 |
| Ait Benhaddou, EH | 1 |
| Benomar, A | 1 |
| Yahyaoui, M | 1 |
| Joutsa, J | 1 |
| Martikainen, K | 1 |
| Vahlberg, T | 1 |
| Kaasinen, V | 1 |
| Jung, SK | 1 |
| Lundblad, M | 1 |
| Usiello, A | 1 |
| Carta, M | 1 |
| Håkansson, K | 1 |
| Fisone, G | 1 |
| Cenci, MA | 1 |
| Ferenci, P | 1 |
| Formann, E | 1 |
| Laferl, H | 1 |
| Gschwantler, M | 1 |
| Hackl, F | 1 |
| Brunner, H | 1 |
| Hubmann, R | 1 |
| Datz, C | 1 |
| Stauber, R | 1 |
| Steindl-Munda, P | 1 |
| Kessler, HH | 1 |
| Klingler, A | 1 |
| Gangl, A | 1 |
| Giroux, ML | 1 |
| Wolters, A | 1 |
| Benecke, R | 1 |
| Hauser, RA | 1 |
| Rascol, O | 1 |
| Korczyn, AD | 3 |
| Jon Stoessl, A | 1 |
| Watts, RL | 1 |
| Poewe, W | 1 |
| De Deyn, PP | 1 |
| Lang, AE | 1 |
| Uitti, RJ | 1 |
| Rajput, AH | 1 |
| Ahlskog, JE | 1 |
| Offord, KP | 1 |
| Schroeder, DR | 1 |
| Ho, MM | 1 |
| Prasad, M | 1 |
| Rajput, A | 1 |
| Basran, P | 1 |
| Zimmermann, C | 1 |
| Hohlfeld, R | 1 |
| Munakata, M | 1 |
| Kato, R | 1 |
| Yokoyama, H | 1 |
| Haginoya, K | 1 |
| Tanaka, Y | 1 |
| Kayaba, J | 1 |
| Kato, T | 1 |
| Takayanagi, R | 1 |
| Endo, H | 1 |
| Hasegawa, R | 1 |
| Ejima, Y | 1 |
| Hoshi, K | 1 |
| Iinuma, K | 1 |
| Hassin-Baer, S | 1 |
| Treves, TA | 1 |
| Simon, ES | 1 |
| Shabtai, H | 1 |
| Orlov, Y | 1 |
| Kandinov, B | 1 |
| Paleacu, D | 1 |
| Paci, C | 1 |
| Thomas, A | 1 |
| Onofrj, M | 1 |
| Suchowersky, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease[NCT04287543] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2021-05-31 | Withdrawn (stopped due to Due to the COVID-19 pandemic, we were unable to begin the study) | ||
| Experimentally-induced Freezing of Gait in Parkinson's Disease by Modulating Step Length/Asymmetry and Cognitive/Visual Loading[NCT04799613] | 20 participants (Anticipated) | Interventional | 2021-03-15 | Not yet recruiting | |||
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
5 reviews available for amantadine and Disease Exacerbation
| Article | Year |
|---|---|
Updates in the medical management of Parkinson disease.
Topics: Age Factors; Amantadine; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Cholinergi | 2012 |
Parkinson disease: managing a complex, progressive disease at all stages.
Topics: Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Gait; Humans; Levodopa; Pa | 2007 |
[Diagnosis and treatment of tremor in Parkinson's disease and essential tremor].
Topics: Adrenergic beta-Antagonists; Amantadine; Anticonvulsants; Antiparkinson Agents; Deep Brain Stimulati | 2007 |
['Fatigue' in multiple sclerosis].
Topics: Amantadine; Aminopyridines; Disease Progression; Fatigue; Female; Humans; Male; Multiple Sclerosis; | 1999 |
Parkinson's disease: medical treatment of moderate to advanced disease.
Topics: Amantadine; Anti-Anxiety Agents; Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; | 2002 |
4 trials available for amantadine and Disease Exacerbation
| Article | Year |
|---|---|
Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
Topics: Amantadine; Antibodies, Monoclonal; Antilymphocyte Serum; Antiviral Agents; Disease Progression; Dru | 2008 |
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Topics: Adult; Amantadine; Antiviral Agents; Disease Progression; Double-Blind Method; Drug Carriers; Drug T | 2006 |
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Topics: Aged; Amantadine; Antiparkinson Agents; Disability Evaluation; Disease Progression; Double-Blind Met | 2007 |
Amantadine for dyskinesia in patients affected by severe Parkinson's disease.
Topics: Aged; Amantadine; Antiviral Agents; Disease Progression; Dopamine Agents; Drug Administration Schedu | 2001 |
16 other studies available for amantadine and Disease Exacerbation
| Article | Year |
|---|---|
Delayed amantadine toxicity causing apparent progression of multiple sclerosis.
Topics: Amantadine; Disease Progression; Fatigue; Female; Humans; Multiple Sclerosis; Multiple Sclerosis, Ch | 2021 |
Repeated Intravenous Amantadine Infusions in Advanced Parkinsonism: Experience of a Large Movement Disorder Center.
Topics: Accidental Falls; Aged; Amantadine; Disease Progression; Dopamine Agents; Dose-Response Relationship | 2019 |
Fatal familial insomnia presenting with agrypnia excitata and very low atonia index level: A case report and literature review.
Topics: Amantadine; Diagnosis, Differential; Disease Progression; Dopamine Agents; Fatal Outcome; Humans; Hy | 2018 |
Frontal Traumatic Brain Injury in Rats Causes Long-Lasting Impairments in Impulse Control That Are Differentially Sensitive to Pharmacotherapeutics and Associated with Chronic Neuroinflammation.
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Amantadine; Amphetamine; Animals; Atomoxetine Hydrochlo | 2016 |
Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Blood Platelets; Disease Progression; Female; Humans; | 2009 |
Excessive daytime somnolence in spinocerebellar ataxia type 1.
Topics: Activities of Daily Living; Amantadine; Ataxin-1; Ataxins; Brain Stem; Cerebellum; Citalopram; Dextr | 2010 |
Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C.
Topics: Adult; Amantadine; Antigens, CD; Antiviral Agents; Disease Progression; Female; Follow-Up Studies; G | 2010 |
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.
Topics: Amantadine; Antiparasitic Agents; Carbidopa; Catechols; Decision Making; Deep Brain Stimulation; Dis | 2012 |
Profile of multiple system atrophy in Moroccan patients attending a movement disorders outpatient clinic in Rabat university hospital.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Amantadine; Disease Progression; Dopamine Agonists; Fe | 2013 |
Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
Topics: Aged; Amantadine; Antidepressive Agents; Antiparkinson Agents; Data Collection; Depression; Disease | 2012 |
A young onset Parkinson's patient: a case study.
Topics: Activities of Daily Living; Adult; Age of Onset; Amantadine; Antiparkinson Agents; Carbidopa; Combin | 2004 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal | 2005 |
Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Uptake Inhi | 1996 |
Combined therapy with hypothermia and anticytokine agents in influenza A encephalopathy.
Topics: Amantadine; Brain; Child, Preschool; Cytokines; Disease Progression; Encephalitis, Viral; Female; Gl | 2000 |
An open trial of amantadine and buspirone for cerebellar ataxia: a disappointment.
Topics: Adult; Aged; Amantadine; Buspirone; Cerebellar Ataxia; Clinical Trials as Topic; Disease Progression | 2000 |
Freezing of gait in patients with advanced Parkinson's disease.
Topics: Adult; Age of Onset; Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Femal | 2001 |